{"denoms":[{"counts":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"83"},{"groupId":"BG003","value":"248"}],"units":"Participants"}],"groups":[{"description":"Participants received 20 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"BG000","title":"Arm A - Panobinostat (20 mg, TIW)"},{"description":"Participants received 20 mg panobinostat BIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"BG001","title":"Arm B - Panobinostat (20 mg, BIW)"},{"description":"Participants received 10 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"BG002","title":"Arm C - Panobinostat (10 mg, TIW)"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"45","upperLimit":"83","value":"67.0"},{"groupId":"BG001","lowerLimit":"47","upperLimit":"87","value":"65.0"},{"groupId":"BG002","lowerLimit":"33","upperLimit":"84","value":"66.0"},{"groupId":"BG003","lowerLimit":"33","upperLimit":"87","value":"66.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"112"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"136"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"130"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"14"}],"title":"Southeast Asian"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"18"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"66"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"20"}],"title":"Unknown/Not Reported"}],"title":"Ethnicity"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"68"},{"groupId":"BG003","value":"213"}],"title":"Caucasian"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"23"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"9"}],"title":"Other"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"118"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"116"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"14"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"4"}]}],"description":"Scale to assess disease progression and disease effects on daily living abilities, as well as determine appropriate treatment and prognosis. Status range includes: 0 (fully active); 1 (restricted physical activity); 2 (unable to carry out work activities); 3 (limited self-care); 4 (completely disabled).","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"Full analysis set (FAS): all participants to whom study treatment was assigned by randomization."}